BeOne Medicines (ONC) Stock Forecast & Price Target

Compare

838 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ONC Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

BeOne

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ONC Stock 12 Month Forecast

Average Price Target

$397.66

▲(24.63% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is $397.66 with a high forecast of $424.00 and a low forecast of $362.00. The average price target represents a 24.63% change from the last price of $319.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"183":"$183","304":"$304","425":"$425","243.5":"$243.5","364.5":"$364.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":424,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$424.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":397.66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$397.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":362,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$362.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[183,243.5,304,364.5,425],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,335.6,342.40000000000003,349.20000000000005,356,362.8,369.6,376.40000000000003,383.2,390,396.8,403.6,410.4,417.2,{"y":424,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,335.6,340.37384615384616,345.14769230769235,349.9215384615385,354.6953846153846,359.4692307692308,364.24307692307696,369.0169230769231,373.79076923076923,378.5646153846154,383.33846153846156,388.1123076923077,392.8861538461539,{"y":397.66,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,335.6,337.63076923076926,339.6615384615385,341.69230769230774,343.7230769230769,345.75384615384615,347.7846153846154,349.81538461538463,351.84615384615387,353.8769230769231,355.9076923076923,357.9384615384615,359.96923076923076,{"y":362,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":205.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":224.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$424.00

Average Price Target$397.66

Lowest Price Target$362.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

$400

Buy

25.37%

Upside

Reiterated

12/10/25

Truist Financial Sticks to Their Buy Rating for BeOne Medicines (ONC)We reiterate our Buy rating and $400PT.

Michael Schmidt

Guggenheim

$400

Buy

25.37%

Upside

Reiterated

12/09/25

BeOne Medicines (ONC) Receives a Buy from GuggenheimWe reaffirm our Buy rating and positive conviction on the stock.

Leonid Timashev

RBC Capital

$408

Buy

27.88%

Upside

Reiterated

12/07/25

RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)

Clara Dong

Jefferies

$420

Buy

31.64%

Upside

Reiterated

11/25/25

Jefferies Sticks to Its Buy Rating for BeOne Medicines (ONC)

Jill Wu

CMB International Securities

$359.47→$392.43

Buy

23.00%

Upside

Reiterated

11/10/25

BeOne Medicines (ONC) Receives a Buy from CMB International SecuritiesWe maintain our Buy rating on BeOne, with a revised target price of US$392.43.

Sean Laaman

Morgan Stanley

$383→$390

Buy

22.23%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $390 from $383 at Morgan StanleyBeOne Medicines price target raised to $390 from $383 at Morgan Stanley

Yigal Nochomovitz

Citi

$399→$405

Buy

26.94%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $405 from $399 at CitiBeOne Medicines price target raised to $405 from $399 at Citi

Gena Wang

Barclays

$385

Buy

20.67%

Upside

Reiterated

11/07/25

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

$389→$402.2

Buy

26.06%

Upside

Reiterated

11/07/25

BeOne Medicines (ONC) Receives a Buy from Bank of America Securities

Reni Benjamin

Citizens JMP

$348→$396

Buy

24.11%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $396 from $348 at Citizens JMPBeOne Medicines price target raised to $396 from $348 at Citizens JMP

Yaron Werber

TD Cowen

$424

Buy

32.89%

Upside

Reiterated

11/06/25

BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating

Rebecca Liang

Bernstein

$259→$362

Hold

13.46%

Upside

Reiterated

10/09/25

Bernstein Remains a Hold on BeOne Medicines (ONC)

Jessica Fye

J.P. Morgan

$345→$385

Buy

20.67%

Upside

Reiterated

10/08/25

BeOne Medicines (ONC) Receives a Buy from J.P. Morgan

Andrew Berens

Leerink Partners

$334→$345

Buy

8.13%

Upside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Unknown Analyst

UBS

Not Ranked

UBS

$326→$373

Buy

16.91%

Upside

Reiterated

08/07/25

UBS Sticks to Its Buy Rating for BeOne Medicines (ONC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

$400

Buy

25.37%

Upside

Reiterated

12/10/25

Truist Financial Sticks to Their Buy Rating for BeOne Medicines (ONC)We reiterate our Buy rating and $400PT.

Michael Schmidt

Guggenheim

$400

Buy

25.37%

Upside

Reiterated

12/09/25

BeOne Medicines (ONC) Receives a Buy from GuggenheimWe reaffirm our Buy rating and positive conviction on the stock.

Leonid Timashev

RBC Capital

$408

Buy

27.88%

Upside

Reiterated

12/07/25

RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)

Clara Dong

Jefferies

$420

Buy

31.64%

Upside

Reiterated

11/25/25

Jefferies Sticks to Its Buy Rating for BeOne Medicines (ONC)

Jill Wu

CMB International Securities

$359.47→$392.43

Buy

23.00%

Upside

Reiterated

11/10/25

BeOne Medicines (ONC) Receives a Buy from CMB International SecuritiesWe maintain our Buy rating on BeOne, with a revised target price of US$392.43.

Sean Laaman

Morgan Stanley

$383→$390

Buy

22.23%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $390 from $383 at Morgan StanleyBeOne Medicines price target raised to $390 from $383 at Morgan Stanley

Yigal Nochomovitz

Citi

$399→$405

Buy

26.94%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $405 from $399 at CitiBeOne Medicines price target raised to $405 from $399 at Citi

Gena Wang

Barclays

$385

Buy

20.67%

Upside

Reiterated

11/07/25

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

David Li

Bank of America Securities

$389→$402.2

Buy

26.06%

Upside

Reiterated

11/07/25

BeOne Medicines (ONC) Receives a Buy from Bank of America Securities

Reni Benjamin

Citizens JMP

$348→$396

Buy

24.11%

Upside

Reiterated

11/07/25

BeOne Medicines price target raised to $396 from $348 at Citizens JMPBeOne Medicines price target raised to $396 from $348 at Citizens JMP

Yaron Werber

TD Cowen

$424

Buy

32.89%

Upside

Reiterated

11/06/25

BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating

Rebecca Liang

Bernstein

$259→$362

Hold

13.46%

Upside

Reiterated

10/09/25

Bernstein Remains a Hold on BeOne Medicines (ONC)

Jessica Fye

J.P. Morgan

$345→$385

Buy

20.67%

Upside

Reiterated

10/08/25

BeOne Medicines (ONC) Receives a Buy from J.P. Morgan

Andrew Berens

Leerink Partners

$334→$345

Buy

8.13%

Upside

Reiterated

08/07/25

BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Unknown Analyst

UBS

Not Ranked

UBS

$326→$373

Buy

16.91%

Upside

Reiterated

08/07/25

UBS Sticks to Its Buy Rating for BeOne Medicines (ONC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

1 Month

xxx

Success Rate

8/14 ratings generated profit

Average Return

+2.89%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +2.89% per trade.

3 Months

xxx

Success Rate

6/10 ratings generated profit

Average Return

+8.87%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +8.87% per trade.

1 Year

Jessica FyeJ.P. Morgan

Success Rate

9/10 ratings generated profit

Average Return

+42.26%

reiterated a buy rating 2 months ago

Copying Jessica Fye's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +42.26% per trade.

2 Years

xxx

Success Rate

9/10 ratings generated profit

Average Return

+53.49%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +53.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONC Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ONC has received 18 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. ONC average Analyst price target in the past 3 months is 397.66.

Each month's total comprises the sum of three months' worth of ratings.

ONC Financial Forecast

ONC Earnings Forecast

Next quarter’s earnings estimate for ONC is $1.50 with a range of $0.50 to $2.70. The previous quarter’s EPS was $1.09. ONC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Sales Forecast

Next quarter’s sales forecast for ONC is $1.46B with a range of $1.40B to $1.52B. The previous quarter’s sales results were $1.41B. ONC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Stock Forecast FAQ

What is ONC’s average 12-month price target, according to analysts?

Based on analyst ratings, BeOne Medicines’s 12-month average price target is 397.66.

What is ONC’s upside potential, based on the analysts’ average price target?

BeOne Medicines has 24.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ONC a Buy, Sell or Hold?

BeOne Medicines has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is BeOne Medicines’s price target?

The average price target for BeOne Medicines is 397.66. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $424.00 ,the lowest forecast is $362.00. The average price target represents 24.63% Increase from the current price of $319.06.

What do analysts say about BeOne Medicines?

BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of ONC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BeOne Medicines (ONC) Stock Forecast & Price Target

ONC Analyst Ratings

ONC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BeOne Medicines

ONC Analyst Recommendation Trends

ONC Financial Forecast

ONC Earnings Forecast

ONC Sales Forecast

ONC Stock Forecast FAQ

Detailed List of Analyst Forecasts